Glenmark Pharmaceuticals Inc., has been granted final approval by the United States Food and Drug Administration for Tacrolimus Ointment, 0.1 percent, the generic version of Protopic 1 Ointment, 0.1 percent, of Leo Pharma AS. According to IQVIATM sales data for the 12 month period ending February 2018, the Protopic Ointment, 0.1 percent market achieved annual sales of approximately USD 109.0 million.
Glenmark’s current portfolio consists of 132 products authorized for distribution in the US marketplace and 61 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. – Medical Buyer Burea